BioPharma Dive February 8, 2024
The heads of Bristol Myers, J&J and Merck backed some affordability measures and supported open biosimilar competition, but with caveats.
The CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate committee hearing Thursday, claiming Americans gain access to cutting-edge medicines months or years earlier than people in countries that pay a fraction of the U.S. costs.
Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders, I-Vt., and his Democratic colleagues pressed Bristol Myers Squibb’s Christopher Boerner, Johnson & Johnson’s Joaquin Duato and Merck & Co.’s Robert Davis to commit to cutting the list prices of top-selling drugs like Eliquis, Stelara and Keytruda to levels in countries like Canada and Japan.
“We are aware...
Today's Sponsors
Today's Sponsor